Drugs / Ortho Tri-Cyclen LO
Ortho Tri-Cyclen LO
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ORTHO TRI-CYCLEN LO | — | 2002-08-22 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00752635 | Sep 2004 → Sep 2005 | acne | Johnson & Johnson Taiwan Ltd | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00399685 Comparator | Dec 2006 → Aug 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00635570 Comparator | Jul 2008 → Jan 2009 | — | University of Chicago | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ortho Tri-cyclen Lo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00635570 ↗ |
| Known as | noregestimate-ethinyl estradiol | “TriCilest (noregestimate-ethinyl estradiol), 0.18mg-0.035mg or 0.215mg-0.035mg or 0.25mg-0.035mg, Oral admistration” NCT00752635 ↗ |
| Known as | Norgestimate-ethinyl estradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00752635 ↗ |
| Route | Oral | “Tablets, oral” NCT00399685 ↗ |